Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo

Molecular Biology Reports

Volumn 40, Issue 7, 2013, Pages 4203-4209

  Jiang, Hong Lei ^a   Jin, Jun Zhe ^a   Wu, Dan ^a   Xu, Dong ^a   Lin, Guo Fu ^a   Yu, Hao ^a   Ma, Dong Yan ^a   Liang, Jian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Celastrol; Combination; Hepatocellular carcinoma; PHA 665752

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CASPASE 3; CASPASE 7; CELASTROL; SCATTER FACTOR RECEPTOR; SORAFENIB; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONE; TRIPTERINE; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE CHECKPOINT; CELL MOTION; CELL PROLIFERATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MICE; PROTO-ONCOGENE PROTEINS C-MET; SULFONES; TRITERPENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879411020     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2501-y     Document Type: Article

References (16)

1. Baatarkhuu O, Kim do Y, Bat-Ireedui P, Han KH (2011) Current situation of hepatocellular carcinoma in Mongolia. Oncology 81(Suppl 1):148-151
2. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M (2011) Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 21:401-416
3. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T (1997) Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57:3305-3313
4. Yap TA, de Bono JS (2010) Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 9:1077-1079
5. Grzelakowska-Sztabert B, Dudkowska M (2011) Paradoxical action of growth factors: antiproliferative and proapoptotic signaling by HGF/c-MET. Growth Factors 29:105-118
6. Yap TA, Sandhu SK, Alam SM, de Bono JS (2011) HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets 12:2045-2058
7. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3:S21-S35
8. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355
9. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M (2004) A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 10:6686-6694
10. You H, Ding W, Dang H, Jiang Y, Rountree CB (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879-889
11. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, Luk JM, Sethi G (2012) Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 5:631-643
12. Lau PC, Wong EY (2012) Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines. Pathol Oncol Res 18:357-363
13. Kim S, Lee SH, Kang S, Lee L, Park JD, Ryu DY (2011) Involvement of c-Met- and phosphatidylinositol 3-kinase dependent pathways in arsenite-induced downregulation of catalase in hepatoma cells. Biol Pharm Bull 34:1748-1752
14. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66:4758-4765
15. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, Gu W, Devlin JP, Silverman RB, Morimoto RI (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279:56053-56060
16. Kim Y, Kang H, Jang SW, Ko J (2011) Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 28:175-184